Contraindicated in:
Pregnancy
.Use Cautiously in:
Exercise Extreme Caution in:
CV: hypotension
Derm: rash
F and E: hyperkalemia
GI: nausea
GU: renal impairment
Neuro: fatigue, dizziness, drowsiness, headache
Resp: cough
Misc: ANGIOEDEMA
Drug-drug:
Renal Impairment
Renal Impairment
Absorption: 37% absorbed after oral administration.
Distribution: Unknown.
Protein Binding: 95%.
Half-Life: Benazeprilat: 10–11 hr.
(antihypertensive effect)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 1 hr* | 1–2 wk‡ | 24 hr‡ |
*After single dose.
‡Chronic dosing.
May cause fetal harm. Advise women of reproductive potential to use effective contraception during therapy and notify health care provider if pregnancy is planned or suspected. If pregnancy is detected, discontinue benazepril as soon as possible. Closely observe infants with histories of in utero exposure to ACE inhibitors for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occur, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and substituting for disordered renal function. Advise patient to avoid breastfeeding during therapy.
NDC Code
